Trastuzumab Deruxtecan
Basal Like
Danish Breast Cancer Cooperative Groupantibody_drug_conjugatePhase 3Active
B
60/ 100
Provisional rating · Methodology v0.2
Rating breakdown
- Clinical Evidence
- 45/ 100
- Competitive Position
- 95/ 100
Competitive context
2 Active assets in the Basal Like cohort.
| Asset / Sponsor | Phase | Rating |
|---|---|---|
Ribociclib Danish Breast Cancer Cooperative Group | Phase 3 | B |
Abemaciclib Danish Breast Cancer Cooperative Group | Phase 3 | B |
Veliparib National Cancer Institute (NCI) | Phase 1 | CC |
Same molecule, other indications
Trastuzumab Deruxtecan is also rated in:
Are you the sponsor?
Submit your data room for a Verified Rating. The public-data rating remains visible alongside.
Contact →